lobbying_activities: 2378709
Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API
This data as json
| id | filing_uuid | filing_type | registrant_name | registrant_id | client_name | filing_year | filing_period | issue_code | specific_issues | government_entities | income_amount | expense_amount | is_no_activity | is_termination | received_date |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2378709 | 4de8d4a2-414e-4860-aaf7-b13b672d91c5 | Q4 | NATIONAL COMMITTEE TO PRESERVE SOCIAL SECURITY AND MEDICARE | 27467 | NATIONAL COMMITTEE TO PRESERVE SOCIAL SECURITY AND MEDICARE | 2019 | fourth_quarter | MMM | Drug Pricing. H.R. 3, the Lower Drug Costs Now Act: Proposals authorizing the Secretary of Health and Human Services (HHS) to negotiate drug prices on behalf of Medicare with pharmaceutical manufacturers; creating a maximum price for any negotiated drug with an international price index (Average International Market price), requiring drug manufacturers that refuse to negotiation with HHS to pay a non-compliance fee of 65% of the gross sales of the drug in question; requiring drug companies that raised the price of a drug in Medicare above the rate of inflation since 2016 to either lower the price or pay the entire price above inflation in a rebate back to the Treasury; creating a $2,000 Medicare beneficiary annual out-of-pocket cost cap for prescription drugs. Drug Pricing. S. 2543, the Prescription Drug Pricing Reduction Act of 2019: Proposals to require pharmaceutical manufacturers to rebate Medicare if they raise prices for drugs covered by Medicare Parts B and D faster than inflation; to establish an out-of-pocket spending limit in which Medicare beneficiaries would pay no more than $3,100 a year on drug costs; to require Medicare Part D private insurers to pay 60% and, drug manufacturers 20%, of the costs incurred over the out-of-pocket spending cap; to increase transparency into pharmacy benefit manager practices and manufacturer drug pricing decisions; and to provide state Medicaid programs with increased authority to contain drug prices. Medicaid Home and Community-Based Services. H.R. 1865: Proposals to extend permanently the spousal impoverishment protections for Medicaid home and community-based services and to extend permanently Money Follows the Person which provides grants to states for initiatives for people requiring long term care to receive Medicaid services and supports in their homes. Medicare Prescription Drug Costs. (No bill): Proposal to require pharmacists to disclose to patients when the the patient copayment exceeds the total cost of the drug to their insurer or pharmacy benefits manager. Medicare Prescription Drug Costs. (No bill): Provisions of the United States-Mexico-Canada Agreement (formerly the North American Free Trade Agreement) addressing countries having expansive regulatory approval monopolies for biologic drugs and restricting the ability of Congress to reform patent laws that drive up drug costs for Medicare. Medicare Prescription Drug Costs, H.R. 1865: Proposal to reduce the threshold for entering the catastrophic phase of the Part D benefit to a point where seniors only pay five percent of their drug costs instead of 25%. Medicare Coverage Expansion. H.R 3, the Lower Drug Costs Now Act: Proposals to expand Medicare coverage to include, vision, dental and hearing benefits. Medicare Coverage Expansion. H.R. 3, the Lower Drug Costs Now Act: Proposals to expand eligibility for the Low-Income Subsidy and Medicare Savings Program. Medicare Open Enrollment. (No bill): Proposals to ensure the Centers for Medicare and Medicaid Services conducts open enrollment in a manner that is unbiased toward the traditional Medicare program. Medigap Reform. H.R. 3, the Lower Drug Costs Now Act: Proposal to improve quality of coverage and access to Medigap by extending guaranteed issue to disabled people and other beneficiaries. Medicare Enrollment. H.R. 1865: Proposal to improve beneficiary education tools and extend funding for state health insurance and assistance programs. Reducing Health Care Costs. S. 1895: Proposal to eliminate surprise medical billing including out-of-network charges in emergencies. Insulin Costs. H.R. 5444, The Lower Insulin Costs Now Act: Proposal to require the Food and Drug Administration (FDA) to continue reviewing generic insulin applications after the Agencys currently planned March 2020 cut-off date, i.e., ensuring that any existing generic insulin applications would continue to receive FDA review. Medicare Part B Penalty. H.R. 1788: Proposal to cap at two years the period for accrual of the penalty for delayed enrollment into Part B; to prevent individuals with Veterans or retiree coverage or who maintain COBRA coverage through a former employer from having to pay the Part B penalty for the remainder of the time they are covered under Part B. Medicare Savings Program. H.R. 4671: Proposal to reduce cost-sharing, align income and resource eligibility tests, simplify enrollment, and other program improvements for low-income Medicare beneficiaries. Medicaid restructuring. (No bill): Proposal by the state of Tennessee to block grant Medicaid. | Administration on Aging,Centers For Medicare and Medicaid Services (CMS),Executive Office of the President (EOP),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Justice, Dept of (DOJ),Labor, Dept of (DOL),Office of Management & Budget (OMB),SENATE,Social Security Administration (SSA),Treasury, Dept of | 220000 | 0 | 0 | 2020-01-09T11:12:27.573000-05:00 |